http://www.pharmachemm.com
Home > Products > Intermediates > Ibrutinib Intermediates > Ibrutinib intermeidate Cas 330786-24-8 Side Effects

Ibrutinib intermeidate Cas 330786-24-8 Side Effects

    Payment Type: L/C,T/T,D/P,Paypal,Money Gram,Western Union
    Incoterm: FOB,CFR,CIF,EXW,FCA,CPT,CIP
    Min. Order: 5 Gram
    Delivery Time: 2 Days
Basic Info

Model No.: Jianfeng

Type: Auxiliaries And Other Medicinal Chemical

Shelf Life: 3 Years

Purity: 99%

Description: WHITE

Grade Standard: Medicine Grade

EINECS: 810-090-0

Form: Powder Form

CAS: 330786-24-8

Storage: Cool

Molecular Formula: C17H13N5O

Additional Info

Packaging: Drum,Package

Productivity: 2000kg

Brand: Jianfeng

Transportation: Ocean,Land,Air

Place of Origin: China

Supply Ability: 2000kg

Certificate: ISO

HS Code: 29349990.99

Port: Qingdao,Shanghai,Tianjin

Product Description
Ibrutinib is a kind of Bruton tyrosine kinase (BTK) inhibitor, it could be used for the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). MCL and CLL are belonged to the B-cell non-Hodgkin's lymphoma, which is difficult to cure and easy to recurrent. Common chemical immunotherapy does not have the targeting, often occurs 3 or 4 adverse reactions. Ibrutinib and B lymphocytes could target with BTK which is necessary for formation, differentiation, and transmission of information, inhibit BTK activity irreversibly, and inhibit tumor cell proliferation and survival effectively. Ibrutinib could be rapidly absorbed after oral administration, during 1~2h reach maximum blood concentration, adverse reactions belong to one or two, therefore, Ibrutinib will become a new choice of treatment of CLL and MCL.
Food and Drug Administration (FDA) of USA has speed up approval of Pharmacyclics Corporation and Johnson & Johnson's Imbruvica (generic name: Ibrutinib) came to market to the cure a kind of rarely aggressive leukemia-mantle cell lymphoma (MCL) in 13th November, 2013. Ibrutinib is a new kind of oral Bruton tyrosine kinase (BTK) inhibitor, it was awarded by FDA be a breakthrough drugs in February of 2013, and approved the MCL and CLL treatments in 13th November, 2013 and 12th February, 2014 respectively. It could covalently bound selectively with cysteine residues (Cys-481) in active site of Btk target protein, irreversible inhibit BTK, thereby effectively prevent tumor cells from migrating from B cell to lymphoid tissue where adapt for tumor growth.

330786 24 8

The other name of the product is Price Ibrutinib intermeidate,Cas 330786-24-8 Side Effects,Package Cas 330786-24-8.

Looking for ideal Price Ibrutinib Intermeidate Manufacturer & supplier ? We have a wide selection at great prices to help you get creative. All the Cas 330786-24-8 Side Effects are quality guaranteed. We are China Origin Factory of Package Cas 330786-24-8. If you have any question, please feel free to contact us.

Product Categories : Intermediates > Ibrutinib Intermediates

Email to this supplier
  • *Subject:
  • *Messages:
    Your message must be between 20-8000 characters
Communicate with Supplier?Supplier
Mr. Vid Mr. Mr. Vid
What can I do for you?
Contact Supplier